Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Oral bioavailability of AM-188 markedly improved by prodrugs: preclinical studies

Nov. 19, 1999

Entecavir: absorption, distribution, metabolism and excretion assessed in preclinical studies

Nov. 18, 1999

Dihydropyrimidines for hepatitis B designed at Bayer

Nov. 18, 1999

DGT and Immunex renew IBD collaboration

Nov. 18, 1999

Effects of IL-10 agonist IT-9302 on immunological markers in acute necrotizing pancreatitis

Nov. 17, 1999

Hoe-140 effective against joint but not intestinal inflammation in rat model

Nov. 17, 1999

Lotronex recommended for approval by FDA advisory committee as IBS treatment

Nov. 17, 1999

7th UEGW: anti-IL-6R MAb evaluated as Crohn's disease Rx

Nov. 16, 1999

Vitamin D3 analogues may allow use of minimum doses of ciclosporin in ulcerative colitis

Nov. 16, 1999

Beneficial preventive and therapeutic effects of halofuginone in liver cirrhosis

Nov. 16, 1999

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.